Rezolute, Inc. stock is down -19.16% since 30 days ago. The next earnings date is Feb 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 9 December’s closed higher than November. 100% of analysts rate it a buy.
Rezolute, Inc. develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.